---
title: "COMPASS Pathways plc (CMPS.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/CMPS.US/overview.md"
symbol: "CMPS.US"
name: "COMPASS Pathways plc"
parent: "https://longbridge.com/zh-CN/quote/CMPS.US.md"
datetime: "2026-04-15T23:14:58.613Z"
locales:
  - [en](https://longbridge.com/en/quote/CMPS.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CMPS.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CMPS.US/overview.md)
---

# COMPASS Pathways plc (CMPS.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 生物技术 |
| 交易所 | US Market |
| 地址 | 33 Broadwick Street, London, Greater London, United Kingdom |
| 官网 | [compasspathways.com](https://compasspathways.com) |

## 公司简介

COMPASS Pathways plc 是一家生物技术公司，专注于英国和美国的心理健康。该公司开发了 COMP360，一种用于治疗耐药性抑郁症的迷幻蘑菇治疗，目前正在进行第三阶段临床试验；同时也在进行第二阶段临床试验，以治疗创伤后应激障碍和神经性厌食症。该公司曾名为 COMPASS Rx Limited，并于 2020 年 8 月更名为 COMPASS Pathways plc。公司成立于 2020 年，总部位于英国伦敦

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Kabir Kumar Nath | CEO & Director |
| Gino Santini | Independent Chairman |
| Teri Loxam | Chief Financial Officer |
| Guy Goodwin | Chief Medical Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Lars Christian Wilde | Senior Advisor |
| Annalisa Lisa Mary Jenkins | Independent Non-Executive Director |
| Daphne Karydas | Independent Director |
| David York Norton | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| RTW Investments, LP | 6.79% | 2025-12-31 |
| Deep Track Capital, LP | 5.69% | 2025-12-31 |
| AtaiBeckley Inc. | 3.70% | 2026-01-21 |
| GMT Capital Corp. | 2.21% | 2025-12-31 |
| The Toronto-Dominion Bank | 1.96% | 2025-12-31 |
| ARK Investment Management LLC | 1.67% | 2025-12-31 |
| George Jay Goldsmith | 1.59% | 2025-03-31 |
| UBS Asset Management AG | 1.58% | 2025-12-31 |
| Ekaterina Malievskaia | 1.57% | 2025-03-31 |
| Two Sigma Investments, LP | 1.28% | 2025-12-31 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**